Aradigm Corporation Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.